Wednesday, November 18, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
How to earnPaparazzi InkBack PageHolder perksLeaderboardAssignmentsContestsLeagueCity
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsCity LeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundToken utilityRobinhood Chain launchesRobinhood Chain projectsPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 57

FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer

The FDA has cleared Janssen Biotech's Rybrevant Faspro for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease worsened after platinum-based chemotherapy and immunotherapy. It's the first new approval for this patient group in a decade, backed by a 42% response rate in a 102-patient trial.

By the Paparazzi desk November 17, 2026 · 5:19 PM · medicalxpress.com · 0 views
Fact boxTrust 50/100 · Developing
What we verified
  • Original source: medicalxpress.com.
  • The source published it on Nov 17, 2026 at 5:19 PM.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.

The U.S. Food and Drug Administration approved Janssen Biotech's Rybrevant Faspro, a combination of amivantamab and hyaluronidase-lpuj, for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease has progressed during or after platinum-based chemotherapy and immunotherapy. The clearance comes as an accelerated approval, and it marks the first drug approved for recurrent or metastatic HNSCC in patients previously treated with platinum-based chemotherapy in 10 years.

The decision rests on a trial of 102 patients with recurrent or metastatic HNSCC. Rybrevant Faspro posted an overall response rate of 42%, against 20% for currently approved therapies. Among patients who responded to the drug, 56% saw that response hold for six months or longer.

Sponsored

The label carries a carve-out: Rybrevant Faspro is not indicated for oropharyngeal squamous cell carcinoma linked to human papillomavirus.

Angelo De Claro, M.D., director of the FDA Oncology Center of Excellence, framed the approval as a turning point for a hard-to-treat population. In a statement, he called it a meaningful step forward for patients with HNSCC, noting that treatment options have historically been limited and outcomes remain poor.

TopicsFDA · Janssen Biotech · Rybrevant Faspro · amivantamab · Angelo De Claro · head and neck squamous cell carcinoma

Share

Source: medicalxpress.com

Written by AI from verified reporting.

More stories

  • Health & science 33 minutes ago · medicalxpress.com · 1 view
    FDA clears Sunharbo, first factor XIa inhibitor to prevent second strokes
  • Health & science 4 hours ago · france24.com · 1 view
    WHO warns drug resistance is outpacing the world's response
  • Health & science 7 hours ago · aol.com · 2 views
    FDA Approves Beren's LEMBAZ, First Drug to Improve Survival in Infantile NPC
  • Health & science 8 hours ago · fiercepharma.com · 1 view
    GSK's Nelkarmi wins FDA nod for ALK lung cancer, capping a three-approval run
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.